ClinicalTrials.gg
RecruitingNCT07171983Updated Oct 1, 2026

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis

A Phase 1 interventional study of BMS-986454 and Placebo in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Recruiting at 9 sites in India. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Updated Oct 1, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb — 4 open to participants now, 8 under way, 2 of them phase 3. Arthritis, Rheumatoid · Bristol-Myers Squibb.

Planned enrollment
48th of 58
46 · median 121
Started
2026
with 2 others
Phase 1
19 of 92
3 open now
Registered
90th of 92
by date

Among the 92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb, this one is the 48th largest by planned enrollment of the 58 interventional ones that give a count, is one of 3 that started in 2026, is one of 19 in phase 1, and was the 90th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-986454 in participants with Rheumatoid Arthritis

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis (RA)
  • Autoimmune Disease
  • Chronic Inflammatory Disease
  • Methotrexate-Inadequate Responders (MTX-IR)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with Rheumatoid Arthritis must have onset after age 18.
  • Participants who meet 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for RA.
  • Participants must have evidence of swelling in at least 1 joint of the hand or wrist by clinical examination at screening and Day -1.
  • Participants must have been an incomplete responder to prior methotrexate (MTX) treatment.

Exclusion criteria

Exclusion Criteria:

  • Participants must not have any significant medical condition, with the exception of Rheumatoid Arthritis (including but not limited to, neurological, GI, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological, allergic disease, drug allergies, or other major disorders) that, in the Investigator's judgment, will substantially increase the risk to the participant if he or she participates in the study.
  • Participants must not have any condition aside from RA that confounds the ability to interpret data from the study.
  • Participants must not have severe Rheumatoid Arthritis as assessed by Disease Activity Score 28 c-reactive protein (DAS28-CRP) at screening or Day -1.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    Part A: Administration of BMS-986454

    Drug: BMS-986454

  • Placebo comparator
    Part A: Placebo

    Other: Placebo

  • Experimental
    Part B: Administration of BMS-986454

    Drug: BMS-986454

  • Placebo comparator
    Part B: Placebo

    Other: Placebo

Interventions

  • DrugBMS-986454

    Specified dose on specified days

  • OtherPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to 6 months

  2. Number of participants with serious adverse events (SAEs)

    Time frame: Up to 6 months

  3. Number of participants with physical examination findings

    Time frame: Up to 6 months

  4. Number of participants with vital sign measurement findings

    Time frame: Up to 6 months

  5. Number of participants with 12-lead electrocardiogram (ECG) findings

    Time frame: Up to 6 months

  6. Number of participants with clinical laboratory test findings

    Time frame: Up to 6 months

Secondary outcomes

  1. Maximum observed concentration (Cmax)

    Time frame: Up to 6 months

  2. Concentration at the end of a dosing interval (Ctau)

    Time frame: Up to 6 months

  3. Trough observed plasma concentration (Ctrough)

    Time frame: Up to 6 months

  4. Time of maximum observed concentration (Tmax)

    Time frame: Up to 6 months

  5. Area under the curve over the dosing interval (AUC(TAU))

    Time frame: Up to 6 months

  6. Area under the serum concentration time curve extrapolated to infinite time (AUC(INF))

    Time frame: Up to 6 months

  7. Area under the serum concentration time curve from time zero to the last quantifiable concentration (AUC(0-T))

    Time frame: Up to 6 months

  8. Terminal-phase half-life (T-HALF)

    Time frame: Up to 6 months

  9. Accumulation index of the area under the curve over the dosing interval (AI_AUC(TAU))

    Time frame: Up to 6 months

  10. Accumulation index of the maximum observed concentration (AI_Cmax)

    Time frame: Up to 6 months

  11. Apparent total body clearance (CLT/F)

    Time frame: Up to 6 months

  12. Apparent volume of distribution of terminal phase (Vz/F)

    Time frame: Up to 6 months

  13. Number of participants with anti-drug antibody (ADA) formation

    Time frame: Up to 6 months

07

Study locations

5 of 9 sites recruiting
  • Nizams Institute Of Medical Sciences
    Hyderabad, Andhra Pradesh 500 082, India
    Recruiting
    • Liza Rajasekhar, Site 0006 · Contact9391008618
  • Apollo Hospitals Ahmedabad
    Ahmedabad, Gujarat 382428, India
    Recruiting
    • Vishnu Sharma, Site 0004 · Contact9978467914
  • Local Institution - 0003
    Bangalore, Karnataka 560 034, India
    Not yet recruiting
    • Site 0003 · Contact
  • Local Institution - 0009
    Mysuru, Karnataka 5700004, India
    Not yet recruiting
    • Site 0009 · Contact
  • All India Institute of Medical Sciences (AIIMS) - Nagpur
    Nagpur, Maharashtra 441108, India
    Recruiting
    • Rajashree Khot, Site 0008 · Contact9823134598
  • Life Point Mutispecialty Hospital Pvt. Ltd.
    Pune, Maharashtra 411057, India
    Recruiting
    • Pathak Ameya Ramchandra, Site 0005 · Contact02066 434366/434343
  • Local Institution - 0007
    Bhubaneswar, Odisha 751024, India
    Active, not recruiting

    Not enrolling at this site.

  • Local Institution - 0002
    Hyderabad, Telangana 500004, India
    Not yet recruiting
    • Site 0002 · Contact
  • Krishna Institute of Medical Sciences Limited
    Secunderabad, Telangana 500003, India
    Recruiting
    • Sarath Veeravalli, Site 0001 · Contact9866000685
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jun 2027, 16 months after the start.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 16 months is above that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2025
First posted
Sep 15, 2025
StartActual
Feb 27, 2026
Primary completionEst.
Jun 28, 2027
CompletionEst.
Aug 25, 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Local Institution - 0007 · Bhubaneswar, India
Show 1 removed
  • Kalinga Institute of Medical Sciences- Bhubaneswar · Bhubaneswar, India
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    1 site added, 1 site removed
    Show site
    • Local Institution - 0007 · Bhubaneswar, India
    Show 1 removed
    • Kalinga Institute of Medical Sciences- Bhubaneswar · Bhubaneswar, India
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07171983
Responsible party
Sponsor
First posted
Sep 15, 2025
Start date
Feb 27, 2026
Primary completion
Jun 28, 2027 (estimated)
Completion
Aug 25, 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion